September 25, 2008
Vancouver, B.C. - EnWave Corporation (TSX-V: ENW) (“EnWave” or “the Company") today announced that it has received positive results from a second shelf-life study of dehydrated rotavirus vaccine conducted by its collaboration partner Aridis Pharmaceuticals, LLC (“ Aridis”) of San Jose, California using EnWave’s bioREV technology.
This second test showed that the sample remained stable at 25˚C throughout the 27-week test period. The test also demonstrated shelf-life stability of over 5 months at 37˚C. The results from the current study compare favourably with manufacturer’s data for the only commercially available lyophilized rotavirus vaccine currently on the market, Rotarix, which is confirmed stable at 37˚C for one week. > Read more
Related Reading
Rotavirus
Rotavirus is the most common cause of severe diarrheal disease in children worldwide and is responsible for the deaths of more than 500,000 children each year, 85 percent of whom live in developing countries. Rotavirus disease cannot be treated with antibiotics or other drugs, and most children will become infected regardless of hygiene practices or access to clean water. Vaccination offers the best hope for preventing severe rotavirus illness.
Click here to access more resources on Rotavirus.
Some key facts about Rotavirus:
>Rotavirus causes severe diarrhea, vomiting, and fever leading to rapid dehydration.
>Rotavirus is found in all countries. Almost every child in the world will suffer at least one infection by the time he or she is 3 years old.
>Providing clean drinking water and otherwise improving sanitation and hygiene do not significantly reduce the spread of rotavirus.
Click here to read more facts on Rotavirus disease and vaccines.
> EnWave Homepage
> Latest News
> Investor Information
> Contact Us |
